4D Molecular Therapeutics (Nasdaq: FDMT) is a late-stage genetic medicine company whose entire equity story turns on a single asset: 4D-150, a one-time intravitreal injection that aims to displace the chronic anti-VEGF injection regimen now dominant in retinal vascular disease. The company had a market cap of about $780 million at the most recent close. The share count stood at roughly 55.2 million, and the company held $430.6 million in cash and marketable securities at the end of the second quarter. The cash position sets a hard floor on the equity and caps the downside for shareholders, which is the feature that makes the binary setup investable rather than speculative.
The setup is a binary event chain. The lead asset is in Phase 3 for wet AMD through two registrational trials, with topline data expected in 2027. A positive readout would make 4D Molecular one of the first companies to commercialize a durable genetic therapy for a major ophthalmology indication. The Otsuka partnership signed in October 2025 pre-sold the Asia-Pacific rights for an $85 million upfront payment. The company is also eligible for up to $335.5 million in milestones and tiered double-digit royalties on net sales in those markets. The counter-thesis is equally clean: if either Phase 3 trial underperforms on vision outcomes or intraocular safety, the equity de-rates toward a pre-data platform valuation, and the pulmonology pipeline is too early to absorb the gap. The current share price prices a meaningful probability of success but not a certainty, which is what makes the risk-reward interesting for investors who can hold through the 2027 data window.